| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6e0b2e2ae9d9b9b6d7591d3999ad8e73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_850a6ebd721cea748b0cbd0f75f297fb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_059babf90e455b4228aeb41f2eed9887 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4756
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-285 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6872
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18 |
| filingDate |
2009-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2013-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ead589ad77fd14c3e15bfb9e5a563323
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_372f05ffff8209feed7f62d7cbbb681c |
| publicationDate |
2013-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8410050-B2 |
| titleOfInvention |
Method for achieving desired glial growth factor 2 plasma levels |
| abstract |
The present invention relates to administering glial growth factor 2 (GGF2) to a patient in need thereof, to achieve serum levels of GGF2 within a desired therapeutic window determined based on the disease or disorder afflicting the patient. In a particular embodiment, the patient is suffering from a disease or disorder associated with reduced levels of myelination and the GGF2 is administered to promote myelination in the patient. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9498515-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10668131-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2013143805-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9744215-B2 |
| priorityDate |
2008-02-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |